非小细胞肺癌新辅助化疗联合伊匹木单抗后的手术结局
本研究基于开放标签Ⅱ期TOP1201试验(NCT01820754),前瞻性收集2013至2017年接受新辅助化疗联合伊匹木单抗后手术的Ⅱ-ⅢA期非小细胞肺癌患者术后数据,并与本院前瞻性胸外科数据库中接受标准术前化疗后手术的历史队列进行比较。结果显示两组30天死亡率均为0%,TOP1201组未出现明显增多的不良手术结局,作者称这是首个证明该方案后可安全、可行切除的报告。
要点
- TOP1201组13例与历史队列42例的30天死亡率均为0%。
- TOP1201组最常见围术期并发症为延长漏气(n=2,15%)和尿路感染(n=2,15%)。
- TOP1201组房颤1例(8%),单纯术前化疗组房颤6例(14%)。
核心结论
- 作者认为,这是首个证明Ⅱ-ⅢA期非小细胞肺癌患者接受伊匹木单抗联合化疗后行手术切除安全、可行的报告。
- 与接受标准术前化疗的患者相比,TOP1201组患者未出现明显增多的不良手术结局。
研究设计与样本
- 开放标签Ⅱ期TOP1201试验(NCT01820754),2013至2017年前瞻性收集新辅助化疗联合伊匹木单抗后手术患者的术后数据。
- TOP1201的手术结局与本院前瞻性胸外科数据库中接受标准术前化疗后手术的历史队列患者进行比较。
- TOP1201组13例接受术前化疗联合伊匹木单抗后手术;历史队列42例接受含铂双药术前化疗(未联合伊匹木单抗)后行肺叶切除或全肺切除。
主要发现
- 两组30天死亡率均为0%。
- TOP1201组最常见的围术期并发症为延长漏气(n=2,15%)和尿路感染(n=2,15%)。
- 单纯术前化疗组最常见的围术期并发症为心房颤动(n=6,14%)。
- TOP1201组心房颤动1例(8%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The objective of this study was to evaluate the safety and feasibility of using neoadjuvant chemotherapy plus ipilimumab followed by surgery as a treatment strategy for stage II-IIIA non-small cell lung cancer. METHODS: From 2013 to 2017, postoperative data from patients who underwent surgery after neoadjuvant chemotherapy plus ipilimumab in the TOP1201 trial, an open label phase II trial (NCT01820754), were prospectively collected. The surgical outcomes from TOP1201 were compared with outcomes in a historical cohort of patients receiving standard preoperative chemotherapy followed by surgery identified from our institution's prospectively collected thoracic surgery database. RESULTS: In the TOP1201 trial, 13 patients were treated with preoperative chemotherapy and ipilimumab followed by surgery. In the historical cohort, 42 patients received preoperative chemotherapy by a platinum doublet regimen preoperative chemotherapy by a platinum doublet regimen without ipilimumab followed by lobectomy or pneumonectomy. The 30-day mortality in both groups was 0%. The most frequently occurring perioperative complications in the TOP1201 group were prolonged air leak (n = 2, 15%) and urinary tract infection (n = 2, 15%). The most common perioperative complication in the preoperative chemotherapy alone group was atrial fibrillation (n = 6, 14%). One patient (8%) had atrial fibrillation in the TOP1201 group. There was no apparent increased occurrence of adverse surgical outcomes for patients in the TOP1201 group compared with patients receiving standard of care neoadjuvant chemotherapy alone before surgery for stage II-IIIA non-small cell lung cancer. CONCLUSIONS: This report is the first to demonstrate the safety and feasibility of surgical resection after treatment with ipilimumab and chemotherapy in stage II-IIIA non-small-cell lung cancer.
引用
- Yang CJ, McSherry F, Mayne NR, et al. Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer. Ann Thorac Surg. 2017. PMID: 29258674. doi:10.1016/j.athoracsur.2017.09.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。